Bio Green Med Solution, Inc. (BGMS)
NASDAQ: BGMS · Real-Time Price · USD
1.630
-0.085 (-4.96%)
At close: Dec 9, 2025, 4:00 PM EST
1.650
+0.020 (1.23%)
After-hours: Dec 9, 2025, 7:17 PM EST
Bio Green Med Solution Revenue
Bio Green Med Solution had revenue of $81.00K in the quarter ending September 30, 2025, with 710.00% growth. This brings the company's revenue in the last twelve months to $-346.00K.
Revenue (ttm)
$-346.00K
Revenue Growth
+9.46%
P/S Ratio
21.95
Revenue / Employee
$6,750
Employees
12
Market Cap
7.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Dec 31, 2024 | 43.00K | - | - |
| Mar 31, 2024 | - | - | - |
| Dec 31, 2023 | 420.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 150.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 843.00K | -1.10M | -56.64% |
| Dec 31, 2015 | 1.94M | 210.00K | 12.11% |
| Dec 31, 2014 | 1.73M | 650.00K | 59.96% |
| Dec 31, 2013 | 1.08M | 1.02M | 1,471.01% |
| Dec 31, 2012 | 69.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 112.00K | -799.00K | -87.71% |
| Dec 31, 2009 | 911.00K | 34.00K | 3.88% |
| Dec 31, 2008 | 877.00K | 748.00K | 579.84% |
| Dec 31, 2007 | 129.00K | -258.00K | -66.67% |
| Dec 31, 2006 | 387.00K | -1.72M | -81.59% |
| Dec 31, 2005 | 2.10M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BGMS News
- 26 days ago - Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - GlobeNewsWire
- 5 months ago - Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
- 5 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - GlobeNewsWire
- 5 months ago - CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT - GlobeNewsWire
- 5 months ago - Cyclacel Pharmaceuticals Announces Stock Split - GlobeNewsWire
- 6 months ago - Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock - GlobeNewsWire